Summary of Sunrise Pipeline Data Conference Call Company and Industry - **Company**: Rezolute - **Industry**: Pharmaceutical/Biotechnology, specifically focusing on treatments for congenital hyperinsulinism (HI) and tumor hyperinsulinism (HI) Core Points and Arguments 1. **Study Results**: The Phase 3 Sunrise study for ersodetug in patients with congenital HI did not achieve statistical significance for primary and secondary endpoints, which was unexpected and disappointing for the company [2][8][14] 2. **Patient Population**: The study involved an ultra-rare pediatric population, which presents unique challenges in clinical trials, including the management of glucose levels by families [3][4] 3. **Regulatory Engagement**: The FDA has shown a willingness to reconsider study designs for ultra-rare diseases, which may provide a pathway for future studies [4][5][6] 4. **Financial Position**: As of September 30, 2025, the company reported having $150 million in cash, allowing it to pursue its objectives despite the study setback [6][45] 5. **Operational Adjustments**: The company plans to decrease operating expenses, which may include a reduction in workforce [6][7] 6. **Open-Label Extension**: More than 50 children from the Sunrise study are now on ersodetug as part of an open-label extension, with some weaned off other therapies, indicating potential efficacy [3][9][67] 7. **Safety Observations**: The safety profile of ersodetug was generally favorable, with a low incidence of serious allergic reactions [12][13] 8. **Placebo Effect**: The study observed a significant placebo response, complicating the interpretation of the results [14][33][39] 9. **Future Studies**: The company is committed to engaging with the FDA to explore alternative study designs for congenital HI and is optimistic about the tumor HI study, which has a different endpoint [5][21][63] Other Important Content 1. **Study Demographics**: The study enrolled 63 participants, with a high retention rate, indicating strong family commitment despite the challenges of frequent visits for treatment [9][10] 2. **Background Therapies**: Many participants were on standard care therapies, which may have influenced baseline hypoglycemia rates [10][11] 3. **Adverse Events**: Hypertrichosis was noted as a common adverse event associated with the study drug, but it was generally mild and less concerning than similar effects from other treatments [13][55][56] 4. **Continuous Glucose Monitoring (CGM)**: The variability in CGM data was noted as a potential limitation in measuring drug performance, suggesting a need for further investigation [51][52] 5. **Future Engagements**: The company plans to meet with advocacy groups and key opinion leaders to discuss the study outcomes and next steps [54][68] This summary encapsulates the key points discussed during the conference call, highlighting the challenges faced by the company and its commitment to addressing the needs of patients with congenital HI.